Shenzhen, China, 11 September 2024 – MGI Tech Co., Ltd. (“MGI”), a company committed to building core tools and technologies that drive innovation in life science, yesterday unveiled its SEQ ALL landscape at its global user conference, the Future of Omics, in Shenzhen and Hong Kong.

“We are thrilled to bring together some of the world’s best life science researchers, academics, clinicians, and collaborators to exchange valuable insights” said Duncan Yu, President of MGI, in his opening remark. “Over the course of our 8-year journey, innovation has always been at the heart of MGI. We continuously strive to deliver cutting-edge technology that empowers diverse applications and expands multi-omics capabilities to unlock new possibilities. We look forward to inspiring innovation and driving exciting developments in the future of omics.”

Sequencing Capabilities to Provide “SEQ ALL”

Dr. Rade Drmanac, Chief Scientific Officer of MGI introduced the term “SEQ ALL” in his speech, which refers to MGI’s competitive capability to offer a myriad of sequencing applications and serving diverse user needs, “MGI is here to offer a unique complete DCS lab for DNA, Cell, and Spatial omics. Together, these technologies define a new generation of MPS (MPS 2.0) and set a new standard in WGS (CompleteWGS). Additionally, MGI now offers CycloneSEQ, the nanopore sequencing technology capable of generating 10kb to 1Mb reads. Now MGI is the only company offering SEQ ALL portfolio, supporting all sequencing applications.  MGI has it all.”

Powered by its advanced massively parallel sequencing (MPS) technology, DNBSEQ™ , with key advantages in efficiency, accuracy, and cost-effectiveness, MGI offers T Series, G Series, and E Series genetic sequencers with data throughput spanning from GB to TB, serving diverse user

needs and scenarios. Earlier this year, MGI launched the Standard MPS 2.0 (SM2.0) upgrade for their DNBSEQ™ platforms, enhancing sequencing quality as reflected by the increased percentage of Q40 bases.

Furthermore, MGI is now distributing CycloneSEQ, a nanopore based single molecule sequencing technolgy enabling 10kb-1Mb reads. Two newly launched sequencers CycloneSEQ-WT02* and CycloneSEQ-WY01* incorporate a range of technological advancements, including enhanced protein engineering, an innovative chip design, and a state-of-the-art basecalling algorithm, to deliver high accuracy and throughput in sequencing.

For more details please visit: https://en.mgi-tech.com/news/507/

Leveraging its robust suite of technologies, MGI strengthens its position as a leading life science technology provider by offering versatile sequencing throughputs and read lengths, short-read and long-read sequencing, single-cell omics, and spatial omics –  collectively defining our “SEQ ALL”

approach.

Expanding multi-omics access globally

Providing highly efficient whole workflow solution for DNA omics, cell omics, spatial omics and multi-omics, MGI is dedicated to empowering omics research to tackle complex biological challenges.

• Multi-omics

Last year, the company launched the DCS Lab Initiative to facilitate global access of multi-omics capabilities. Today, MGI announced at the conference that it has successfully set upa total of 10 DCS labs across China, Germany, and Singapore, leveraging its unique capability in the industry in providing end-to-end solutions for both research and clinical translational applications.

MGI launched DNBSEQ-G400RS FluoXpert, a multi-functional sequencer that is compatible with in vivo spatial protein detection. It is suitable for a wide range of applications in tumor classifications, disease prognosis, tissue microenvironment analysis, and more.

• Spatial Omics

As part of its commitment to providing users the most accessible, comprehensive, and efficient spatial-temporal omics workflow solutions, MGI became an official distributor of a selection of STOmics-related products in July of this year. The Stereo-seq libraries are sequenced on MGI’s flagship DNBSEQ-G400RS and DNBSEQ-T7RS platforms, ensuring high-quality data output.

At the Future of Omics Conference, Stereo-seq Transcriptomics Solution v1.3 (Stereo-seq v1.3), a level-up  STOmics solution designed for Fresh Frozen samples is firstly introduced to customers.

This upgraded version offers significantly improved capture efficiency of the whole transcriptome information with true single-cell resolution.  This product is available for ordering from September. Previously, Stereo-seq OMNI, a revolutionary sequencing-based spatial transcriptomics solution compatible with multiple species, was also released. With Stereo-seq OMNI, users can obtain spatial total RNA information from FFPE samples at single-cell resolution and dive deeper into the molecular changes of precious clinical samples. Through its innovative "Random Probe" design, both total RNA and microbiome information can be detected on the same tissue slide.

• Cell Omics

For cell omics, MGI provides a one-stop platform including DNBelab C Series, for single-cell research from storage and transport to sample preparation, labeling and library preparation, high-throughput sequencing, and data analysis.

At the conference, MGI introduced DNBelab C series High-Throughput Single-Cell 5' RNA & V(D)J Library Preparation Kit. This kit can be used with DNBelab C-TaiM4, a droplet generator previously released, to complete the droplet encapsulation process of cells within 12 minutes. Combined with the DNBC4Tools analysis tool, it can process up to 20,000 cells per slide per run, completing single-cell 5' RNA, TCR, and BCR library preparation and data quality control analysis.

• End-to-End solutions

MGI is uniquely postioned to leverage its suits of automation platforms to develop comprehensive solutions that refine every step of the process, thereby delivering more impactful results. We’ve introduced solutions like low-pass sequencing for agriculture, eDNA for public health and Human microbiome metagenomics sequencing package, to enhance efficiency, accuracy, and research turnaround times, enabling researchers to focus on result analysis rather than labour-intensive tasks.

At the conference, MGI launched the solutions for PopGen Omics. Population genetics deals with genetic differences within and among populations, which has the potential to reach a clearer and deeper understanding of stratification, disease prevention, risk prediction, diagnosis, etc. MGI introduced PopOmics Sequencing Package, providing a different perspective to power discovery across multiple layers of biological information - combining genomics, epigenomics, transcriptomics, and metagenomics into a full individual readout.

Armed with multi-omics capabilities, MGI continues to offer customers extensive product lineup and whole workflow, driving innovation and development in clinical genomics, polulation genomics, public health, animal and plant genomics, environmental genomics and more applications.

In the next 3 days of the Future of Omics conference, more than 60 speakers and 10 ecosystem partners from around the world will present their cutting-edge innovations and advancements in field of Omics. Together, they will exchange insights and collaborate on shaping the breakthroughs of tomorrow.

MGI’s Future of Omics Conference is taking place between 10-13 September 2024 in Shenzhen and Hong Kong. For more information, please visit https://futureofomics.com/

*For research use only. Not for use in diagnostic procedures